VANCOUVER, British Columbia, July 11, 2022 (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a clinical stage Canadian pharmaceutical development company, is pleased to provide an update on its chronic kidney disease (“CKD”) research program with NP-251 (“Repirinast”). In Q1 2022, the Company announced that it had initiated…


Previous articlePsychedelic Bulletin #110 – Psychedelics Docuseries Comes to Netflix; DEA Schedules Public Hearing on Banning 5 Psychedelics
Next articlePT336 – Sisi Li, Ph.D. – Porta Sophia: Psychedelic Prior Art